Université de Sherbrooke
Tamas Fulop, MD, PhD, is Professor of Medicine and Geriatrics, and Senior Researcher at the Research Center on Aging,
University of Sherbrooke, Québec, Canada. He is the deputy director of the Research Center on Aging and member of
the Graduate Immunology Programme. He was the President of the Société Québecoise de Gériatrie from 2007–2012. He
has directed the Biology Research Programme of the Research Center on Aging for more than 10 years. He obtained his
MD degree at Geneva University. He received his PhD in Biochemistry and Immunology from the Hungarian Academy
of Sciences and was a post-doctoral fellow at University Paris XII in Biochemistry. Dr. Fulop’s NSERC and CIHR
funded research since 1994 is focused on immune response changes in T cells and neutrophils and the mechanism of
inflammation with aging and age-related diseases in humans: Dementia, cardiovascular diseases. More specifically his
research is directed to the elucidation of the signal transduction changes in immune cells with specific focus on lipid
rafts. He has authored more than 230 publications. He is recipient of the Presidential Award of the IAGG and fellow of
the GSA since 2001. He served on the executive committee and participated in the organization of three IAG congresses.
He served on the GSA Publications Committee and BS executive committee. He is on the editorial boards of Pathology
Biology, Immunity and Aging, European Geriatric Medicine, Journal of frailty and Aging, Journal of Geriatrics and
Palliative Care, Gerontology and was Section Editor of the BMC open access journal Immunity and Aging. He is the
editor-in-chief of the Interdisciplinary Topics in Gerontology. He is co-director of the undergraduate geriatric teaching
Speaker Abstract(s): S12
Università Vita-Salute San Raffaele, Division of Experimental Oncology, Milano, Italy
Paolo Ghia received his MD from the University of Torino, Italy, followed by a residency in Internal Medicine. He
received his PhD working at the Basel Institute for Immunology, Basel, Switzerland, where he studied the development
of normal human B lymphocytes. He moved to the Dana-Farber Cancer Institute, Harvard Medical School, Boston,
where he studied the molecular mechanisms of the pathogenesis of chronic lymphoproliferative disorders, particularly
of follicular lymphoma.
He is now working in Milano, as Associate Professor in Internal Medicine at the Università Vita-Salute San Raffaele;
and Deputy Chairman of the Division of Experimental Oncology, at the San Raffaele Scientific Institute. He is Head of
the Laboratory of B-Cell Neoplasia and former Scientific Coordinator of the Clinical Unit of Lymphoid Malignancies. He
is now Director of the Strategic Program on CLL, where he is National Coordinator or Principal Investigator in over 20
clinical trials in CLL and related disorders, including phase 1 studies.
His research interest is the study of the molecular and cellular mechanisms acting in the natural history of Chronic
Lymphocytic Leukemia (CLL), including Monoclonal B-cell Lymphocytosis (MBL). On these topics he has published over
170 manuscripts in peer-reviewed journals.
He is President of the European Research Initiative on CLL (ERIC), collaborating to the guidelines for the detection
of Minimal Residual Disease (MRD) for the analysis of the mutational status of the immunoglobulin genes and of the
TP53 gene mutations. He is also a member of the WHO Clinical Advisory Committee for Lymphocytic and Histiocytic
Malignancies for the topic Chronic Lymphocytic Leukemia, MBL, and PLL and associate Editor for CLL at Haematologica,
the official Journal of the European Hematology Association (EHA).
Speaker Abstract(s): S13
Medical Oncology, Paoli Calmettes Institute, Marseille, France
Dr. Marine Gilabert is an associate professor and a medical oncologist from Marseille, France, Aix-Marseille University.
Her medical training and Ph.D was completed at Paoli-Calmettes Institute, Marseille, France in 2011 and 2014
respectively. She received a prestigious Kate McGarrigle Fundation research fellowship which she was undertaking at
Jewish General Hospital, McGill University, Montreal, Canada in 2015. Her main interests are gastrointestinal and
hepatopancreatobiliary cancers. She has been significantly involved in Phase I, II and III clinical trials and is principal
investigator of a numerous translational research.
Speaker Abstract(s): S14
“S.G. Moscati” Hospital, Medical Oncology, Avellino Italy
Cesare Gridelli, MD, is currently Chief of Division of Medical Oncology at the “S.G. Moscati” Hospital, Avellino (Italy).
He has been from December 2003 to February 2016 Director of Department of Oncology/Hematology at the same
institution. He earned his medical degree and residencies in Internal Medicine and then in Medical Oncology at the
“Federico II” University of Naples (Italy). Since 1993 Vice-Chief of Division of Medical Oncology B, National Cancer
Institute of Naples. Since 2001 Chief of Day Hospital Chemotherapy Unit at the same Institute. His areas of expertise
are lung cancer and cancer in the elderly. He is deeply involved in the clinical development of new anticancer targeted